Compare Heron Therapeutics Inc (HRTX) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Newmont Corporation — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Newmont Corporation trades at $117.94 (market cap $119.64B). The key difference: Newmont Corporation is far larger — about 1615.9× Heron Therapeutics Inc's market cap, and Newmont Corporation pays a 0.92% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Newmont Corporation for 58 Days on average.
| HRTX | NEM | |
|---|---|---|
Market Cap | $74.04M | $119.64B |
Volume | 3,668,095 | 4,343,460 |
Sector | Health | Basic Materials |
52-Week High | $1.49 | $135.14 |
52-Week Low | $0.27 | $78.63 |
Typical Hold Time | 35 Days | 58 Days |
Enterprise Value | $180.78M | $116.23B |
Dividend Yield | — | 0.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Newmont (NEM) trades at $113.54, down 2.45% on the day, amid a bearish technical signal but strong fundamental performance. The company reported record free cash flow of $5.3 billion in H1 2026 and has beaten earnings estimates for three consecutive quarters. Revenue grew to $22.67 billion in 2025 with a net income margin of 33.36%, while analyst consensus remains strongly bullish with a $136.83 price target.
The stock presents a compelling value opportunity with a P/E of 14.32 and robust profitability, though near-term technical weakness and gold price volatility pose risks. Upside potential is supported by operational improvements and shareholder returns, but investors must weigh macroeconomic factors affecting the gold sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
